Abstract
Aggressive immunity characterized by the motion of cytotoxic T lymphocytes (CTLs), T helper (Th) 1 cells, and natural killer (NK) cells is the first line of defense against intracellular microorganism invasion and tumor formation. In patients with infectious diseases and tumors, aggressive immunity is often attenuated by immune suppressive effects provided by regulatory T (Treg) cells including CD4+ CD25+ forkhead-box (fox) p3+ T cells, T regulatory (Tr) 1, Th3, and a subpopulation of γδ-type of T cell receptor-expressing T (γδ T) cells. It has been demonstrated that Treg cells down-regulate aggressive immunity by direct cell interactions and suppressive cytokines (e.g., interleukin (IL)-10, transforming growth factor (TGF)-β). Today, instead of synthesizing chemical agents with serious side effects, protein agents, catalytic oligonucleotides, and natural medicines involved in the elimination of Treg cell-mediated suppressive responses for the restoration of aggressive immunity are expected to be alternatives as a mild clinical remedy against microorganism invasion and tumors.
Keywords: Anti-infective immunity, anti-tumor immunity, aptamer, fludarabine, immune suppression, natural medicine, regulatory T cell, mild medicine
Current Medicinal Chemistry
Title: Anti-Infective and Anti-Tumor Agents Based on the Depletion of Immune Suppressive Effects
Volume: 15 Issue: 10
Author(s): Naohiro Seo, Hiromichi Yamashiro and Toshimasa Tadaki
Affiliation:
Keywords: Anti-infective immunity, anti-tumor immunity, aptamer, fludarabine, immune suppression, natural medicine, regulatory T cell, mild medicine
Abstract: Aggressive immunity characterized by the motion of cytotoxic T lymphocytes (CTLs), T helper (Th) 1 cells, and natural killer (NK) cells is the first line of defense against intracellular microorganism invasion and tumor formation. In patients with infectious diseases and tumors, aggressive immunity is often attenuated by immune suppressive effects provided by regulatory T (Treg) cells including CD4+ CD25+ forkhead-box (fox) p3+ T cells, T regulatory (Tr) 1, Th3, and a subpopulation of γδ-type of T cell receptor-expressing T (γδ T) cells. It has been demonstrated that Treg cells down-regulate aggressive immunity by direct cell interactions and suppressive cytokines (e.g., interleukin (IL)-10, transforming growth factor (TGF)-β). Today, instead of synthesizing chemical agents with serious side effects, protein agents, catalytic oligonucleotides, and natural medicines involved in the elimination of Treg cell-mediated suppressive responses for the restoration of aggressive immunity are expected to be alternatives as a mild clinical remedy against microorganism invasion and tumors.
Export Options
About this article
Cite this article as:
Seo Naohiro, Yamashiro Hiromichi and Tadaki Toshimasa, Anti-Infective and Anti-Tumor Agents Based on the Depletion of Immune Suppressive Effects, Current Medicinal Chemistry 2008; 15 (10) . https://dx.doi.org/10.2174/092986708784049603
DOI https://dx.doi.org/10.2174/092986708784049603 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bone Effects of Glitazones and Other Anti-Diabetic Drugs
Current Drug Safety Anti-angiogenic Treatment in Metastatic Colorectal Cancer: Current Issues and Future Aims
Current Cancer Therapy Reviews Women’s Health in Central America: The Complexity of Issues and the Need to Focus on Indigenous Healthcare
Current Women`s Health Reviews Preclinical Drug Metabolism and Pharmacokinetics, and Prediction of Human Pharmacokinetics and Efficacious Dose of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237)
Drug Metabolism Letters Bioinformatic Application in Proteomic Research on Biomarker Discovery and Drug Target Validation
Current Bioinformatics Primary Sjogren’s Syndrome and the Type I Interferon System
Current Pharmaceutical Biotechnology Cell Death: Tipping the Balance of Autoimmunity and Tissue Repair
Current Pharmaceutical Design Role of Advanced Glycation End Products (AGEs) in Osteoporosis in Diabetes
Current Drug Targets Target Identification of Grape Seed Extract in Colorectal Cancer Using Drug Affinity Responsive Target Stability (DARTS) Technique: Role of Endoplasmic Reticulum Stress Response Proteins
Current Cancer Drug Targets The Role of P-Glycoprotein in Psychiatric Disorders: A Reliable Guard of the Brain?
Central Nervous System Agents in Medicinal Chemistry Targeting Microglial Polarization to Improve TBI Outcomes
CNS & Neurological Disorders - Drug Targets The Universal Nature, Unequal Distribution and Antioxidant Functions of Melatonin and Its Derivatives
Mini-Reviews in Medicinal Chemistry Immunotherapeutic Approaches in Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Aflibercept: A Novel VEGF Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Tumors
Mini-Reviews in Medicinal Chemistry Adiponectin and Cardiovascular Disease: Mechanisms and New Therapeutic Approaches
Current Medicinal Chemistry Plant Ribonucleases and Nucleases as Antiproliferative Agens Targeting Human Tumors Growing in Mice
Recent Patents on DNA & Gene Sequences Unraveling Progesterone-Induced Molecular Mechanisms in Physiological and Pathological Conditions
Current Clinical Pharmacology Hydroxychloroquine (HCQ) and its Synthetic Precursors: A Review
Mini-Reviews in Organic Chemistry The In-Situ One-Step Synthesis of a PDC Macromolecular Pro-Drug and the Fabrication of a Novel Core-Shell Micell
Current Pharmaceutical Design Immuno-Isolation in Oncology - A Mini-Review
Current Pharmaceutical Biotechnology